Baxter Healthcare Corporation: MYXREDLIN, Insulin Human in 0.9% Sodium Chloride Injection, 100 units/100 mL (1 unit/mL), Rx only, Baxter Healthcare Corporation, Deerfield,
Read the official notice at FDA (drug) →
Get alerts for Baxter Healthcare
The text below is copied from the official FDA (drug) record. If anything differs, the official notice is correct.
- Company / brand
- Baxter Healthcare Corporation
- Product
- MYXREDLIN, Insulin Human in 0.9% Sodium Chloride Injection, 100 units/100 mL (1 unit/mL), Rx only, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-0126-12.
- Reason / hazard
- CGMP Deviations
- Classification
- Class II
- Status
- Ongoing
- Distribution / sold at
- US Nationwide; Puerto Rico; and Chile.
- Recall initiated
- 2026-08-06
- Code info
- Lot # NC188630, NC188708, NC188791, NC188845, NC188876, NC188968, Exp Date: 12/31/2027; Lot # NC193719, NC193849, Exp Date: 04/30/2028; Lot # NC194051, NC194105, Exp Date: 05/31/2028; Lot # NC195171, Exp Date: 06/30/2028.
- Product quantity
- N/A
- Voluntary mandated
- Voluntary: Firm initiated
- City
- Deerfield
- State
- IL
- Country
- United States
- Event id
- 99500
Free daily digest + "My products" watchlist